Novartis seeks leadership with Cosentyx

For the first time for any biologic, data show almost 80% of ankylosing spondylitis patients on Cosentyx have no radiographic progression of the spine at 4 years.

"The key finding of these data is that patients treated with Cosentyx may now have the opportunity to maintain their mobility for a longer time. This is very important as ankylosing spondylitis is a crippling condition that can impact people in their twenties when they still have many decades of their life ahead of them," said Vas Narasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis. "For the first time for any biologic, Cosentyx shows that almost 80% of patients had no radiographic progression for as long as 4 years. These data demonstrate the potential of Cosentyx to help patients live with less pain and retain their mobility for longer."

These new long-term data add to a growing body of evidence demonstrating the unique position of Cosentyx with lasting efficacy and proven safety across AS, psoriatic arthritis (PsA) and moderate-to-severe psoriasis. Cosentyx is the first and only IL-17A inhibitor approved for AS. Cosentyx is a highly targeted biologic for first-line use in AS, a chronic inflammatory disease that can lead to prolonged pain and mobility loss.